Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome

The European Commission has approved tislelizumab plus chemotherapy as treatment for patients with esophageal and gastric or GEJ cancer.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Tiragolumab with atezolizumab, when compared with placebo with atezolizumab, failed to reach its overall survival end point in patients with NSCLC.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.

Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.